STOCK TITAN

Codexis Inc. - CDXS STOCK NEWS

Welcome to our dedicated news page for Codexis (Ticker: CDXS), a resource for investors and traders seeking the latest updates and insights on Codexis.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Codexis's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Codexis's position in the market.

Rhea-AI Summary
Codexis, Inc. (CDXS) anticipates a 10% growth in 2024 product revenue, excluding enzyme sales related to PAXLOVID™. Recent debt financing strengthens financial position with runway through 2026. Focus on ECO Synthesis™ platform and dsRNA ligase launch. Positive business developments include asset purchases, licensing deals, and technical progress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25%
Tags
earnings
-
Rhea-AI Summary
Codexis, Inc. (NASDAQ: CDXS) partners with Roche for an exclusive global license for its newly engineered dsDNA ligase for NGS library preparation, replacing the prior license on EvoT4™ DNA ligase. The agreement includes upfront and milestone payments, showcasing Codexis' focus on core business areas. The engineered dsDNA ligase, developed using CodeEvolver® technology, offers improved ligation efficiency, higher library yields, and complexity with minimal bias, benefiting NGS workflows.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.69%
Tags
none
-
Rhea-AI Summary
Codexis, Inc. (CDXS) will attend the TD Cowen 44th Annual Health Care Conference in March 2024. Management will participate in a fireside chat on March 4, 2024, at 2:50 pm ET. A live webcast will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.61%
Tags
conferences
Rhea-AI Summary
Codexis, Inc. appoints Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board to support ECO Synthesis™ manufacturing platform. The board now includes experts in oligonucleotide research and development, providing critical insights for the company's strategic direction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.12%
Tags
management
-
Rhea-AI Summary
Codexis, Inc. (CDXS) will report its financial results for Q4 and FY 2023 on February 28, 2024. The company will host a conference call to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.89%
Tags
conferences earnings
-
Rhea-AI Summary
Codexis, Inc. secures a $40 million term loan agreement with Innovatus Capital Partners, LLC to boost cash position and accelerate development of ECO Synthesis™ manufacturing platform for RNAi therapeutics. The loan facility includes $30 million upfront and access to an additional $10 million upon reaching revenue thresholds, reinforcing Codexis' financial strength. The company aims to achieve positive cash flow by the end of 2026, supporting ongoing technology development and commercialization efforts. Codexis plans to build an ECO Synthesis™ Innovation Lab to advance RNAi constructs and nucleotide modifications, enhancing its position in the pharmaceutical manufacturing sector. The partnership with Innovatus signifies confidence in Codexis' growth potential and innovative technology, positioning the company for future success.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.68%
Tags
none
Rhea-AI Summary
SeqWell and Codexis, Inc. announced the development of an engineered high-performance transposase enzyme, TnX transposase, designed to improve next-generation sequencing (NGS) performance. The collaboration leverages Codexis' strength in enzyme engineering and seqWell's expertise in developing tools for NGS. The new transposase is expected to reduce insertion-site bias, increase DNA conversion to library, and improve robustness across a range of assay conditions. Performance data will be presented at the AGBT General Meeting in February 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.45%
Tags
none
-
Rhea-AI Summary
Codexis, Inc. (NASDAQ: CDXS) has entered into a purchase agreement with Nestlé Health Science for CDX-7108, an investigational therapy for exocrine pancreatic insufficiency. Codexis will receive up to $45M in potential milestone payments, including a $5M upfront payment, as well as single-digit net-sales-based royalties. Nestlé Health Science will be solely responsible for the continued development and commercialization of CDX-7108, including all associated costs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.51%
Tags
none
-
Rhea-AI Summary
Codexis, Inc. (NASDAQ: CDXS) has entered into an agreement with Aldevron, a global leader in the custom development and manufacture of plasmid DNA, RNA, and proteins for the biotech industry. Aldevron will acquire a global exclusive license to Codexis’ Codex® HiCap RNA Polymerase, providing a path to a GMP-grade version. Codexis will receive payments for technical milestones, commercial milestones, and sales-based royalties. The collaboration aims to increase commercial penetration and enable efficient manufacture of mRNA-based therapeutics, potentially impacting millions of patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
41.15%
Tags
none
Rhea-AI Summary
Codexis, Inc. (NASDAQ: CDXS) achieves gram-scale synthesis with its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis™ technology, enabling the modeling of manufacturing processes for RNAi therapeutics. Pre-commercial customer testing set for 2024 with a full commercial launch anticipated in 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
41.15%
Tags
none
Codexis Inc.

Nasdaq:CDXS

CDXS Rankings

CDXS Stock Data

245.36M
63.61M
3.22%
82.73%
3.26%
Paint and Coating Manufacturing
Manufacturing
Link
US
Portland

About CDXS

codexis, inc. is a leading protein engineering company applying innovative technologies to unlock the power of proteins™. our proprietary codeevolver® technology platform enables the rapid development and production of highly optimized proteins, custom-designed for your application. codexis’ revolutionary approach to protein engineering starts with an understanding of the desired performance specifications and optimizes a protein specifically to fit these requirements. you get precisely the protein you need for the job you want it to do. guided by proprietary artificial intelligence software and advanced high-throughput screening systems, codexis is able to efficiently generate and introduce function-driven mutations to rapidly improve a protein for its target application. since 2002, codexis’ in-house biochemists, biologists and bioinformatics experts have worked closely with our clients to advance the technologies for protein optimization and production, enabling breakthrough develop